Raymond James upgraded enGene (ENGN) to Strong Buy from Outperform with a price target of $27, up from $23.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENGN:
- enGene’s Detalimogene Shows Promising Results in Bladder Cancer Trial
- Buy Rating for enGene Holdings Amid Anticipated Positive Data from Phase 2 LEGEND Study
- enGene to Discuss New Data from LEGEND Trial for Bladder Cancer Therapy
- enGene Holdings to Present at Key November Investor Conferences
- enGene Holdings Recognized as a Top Workplace in Life Sciences